Ropeginterferon Alfa-2b Has Long-Term Benefits in Polycythemia Vera

Ropeginterferon, the novel pegylated formulation of interferon alfa-2b, demonstrated efficacy, safety, and tolerability compared with hydroxyurea for the treatment of patients with polycythemia vera, according to research unveiled at the 2017 American Society of Hematology Annual Meeting.

 Targeted Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.